On April 1, 2026, Givaudan Active Beauty announced the launch of PrimalHyal 300, a medium-molecular-weight hyaluronic acid intended as a healing accelerator for post-procedure recovery.
According to the company’s press release, PrimalHyal was developed in the Champagne region of France through sustainable innovation in a biorefinery. This innovation works by boosting bleomycin hydrolase levels in skin by 79%, thus helping skin remain hydrated while accelerating natural recovery.
“Our skin is our first line of defense – a complex and dynamic structure that must repair itself effectively when compromised,” said Amandine Scandolera, head of biological evaluation at Givaudan Active Beauty. “PrimalHyal 300 is the result of years of research into how hyaluronic acid can support the skin’s natural repair and cell reconnection processes. By specifically reactivating bleomycin hydrolase production, it helps the skin heal better, faster and more effectively.”
Ex vivo explant models showed PrimalHyal 300’s ability to restore skin barrier strength in just a few days, even after harsh chemical peeling. Further, the company’s tests show that the ingredient significantly increased ceramide content compared to the control. In clinical studies, participants saw a visible improvement in hydration after three days and a substantial reduction in redness and irritation after one week.
Givaudan Active Beauty will be showcasing PrimalHyal 300 at in-cosmetics Global 2026 in Paris, France.
